ProCE Banner Activity

Bispecific Antibodies in the Management of Relapsed/Refractory Follicular Lymphoma


Download this slideset from a live symposium for an expert overview of bispecific T-cell engager therapy in follicular lymphoma, including the latest clinical data, advice on CRS management with these agents, and future directions.

Released: December 07, 2023



Peter Martin

Peter Martin, MD

Chief, Lymphoma Program
Professor of Medicine
Weill Cornell Medicine
Meyer Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from Genentech, a member of the Roche Group; Genmab; Ipsen Biopharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc.

Genentech, a member of the Roche Group


Ipsen Biopharmaceuticals Inc

Regeneron Pharmaceuticals, Inc